Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics
|出版日||ページ情報||英文 108 Pages
|バイオシミラーの世界市場：医療費抑制の動きや、主力生物製剤の特許満了に支えられた、収益性豊かな市場 Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics|
|出版日: 2019年01月01日||ページ情報: 英文 108 Pages||
世界のバイオシミラー市場は今後、45.22%ものCAGR (複合年間成長率) で成長していくと見込まれています。世界各国での医療費削減の動きや、主な医薬品の特許満了などが、主な市場促進要因となっています。他方、開発コストや複雑さ、既存企業の対抗策、互換性の問題などが、市場成長の妨げとなっています。
当レポートでは、世界のバイオシミラー市場における最新の開発・上市動向について分析し、製薬業界が現在直面している問題点や (バイオシミラー開発による) 解決方法、主要なパイプライン製品の治験動向、現在／将来の市場規模、薬剤開発の主な促進・抑制要因、政策当局の動向や規制改訂の動き、といった情報を取りまとめてお届けいたします。
The Global Biosimilar market by product is projected to grow at a compound annual growth rate (CAGR) of 45.22%. The market is driven mainly by a constrained payer environment and patent expiration of several best-selling biologics. However, developmental cost and complexities, strategies from originators and interchangeability concerns pose a challenge to market growth.
A biosimilar is a biotherapeutic that is clinically highly similar to an approved original biologic (reference product) in terms of active ingredients and has no meaningful differences in efficacy and safety. Biosimilars are also known as follow-on biologics or subsequent entry biologics.
A total of 492 products are in development. The Preclinical stage contains the largest number of pipeline products: 232. The late-stage pipeline (Phase III and Pre-registration) account for 24% of the overall pipeline, with 120 products. The global biosimilar pipeline is dominated by companies from emerging markets. The most active companies in the early-stage pipeline are from India and China. South Korean companies such as Celltrion and Samsung Bioepis and Indian companies such as Biocon and Dr. Reddy's Laboratories have a strong late-stage pipeline. Pfizer and Amgen have a strong late-stage pipeline as well.
There exist enormous commercial opportunities for biosimilar manufacturers over the coming years, given the number of high-revenue-generating biologics that will go off patent in the next five years, and promising revenue forecasts for biosimilars in late-stage development. There exist a diverse number of biosimilars in the pipeline for a wide range of therapy areas, with several of these in the later stages of development. Government support for biosimilars is increasing in key mature and emerging markets, given the cost-saving opportunities that these products represent for national healthcare budgets.
The latest report, "Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics" provides an in-depth assessment of the current developments and trends in the global biosimilars market. This report also assesses the state of the biosimilar R&D and commercial landscape through multilevel analytics that include data split by therapy area, stage of development, molecule, and company. Global revenue forecasts to 2024 for biosimilars with strong market potential, both in development and in the market, are provided.
The report also details out current biosimilar regulatory frameworks and guidelines implemented in the US, Europe, Japan, China, South Korea, India and Brazil, and recent developments in the landscape within these markets